Table 1. Summary of the proportion of patients gaining ≥10 letters (BCVA) from baseline to month 12 by study and treatment group.
| Treatment group | ||||||
| Study | Outcome measured at | Ranibizumab 0.5 mg PRN, n/N (%) | Aflibercept 2.0 mg bi-monthly, n/N (%) | Laser, n/N (%) | Sham, n/N (%) | Ranibizumab 0.5 mg PRN + laser, n/N (%) |
| DA VINCI [66] | 12 months | 19/42 (45.2) | 13/44 (29.5) | |||
| VISTA[72] | 12 months | 88/151 (58.3) | 30/154 (19.5) | |||
| VIVID[72] | 12 months | 72/135 (53.3) | 34/132 (25.8) | |||
| DRCR.net Protocol I [67] | 12 months | 81/293 (27.6) | 95/187 (50.8) | |||
| READ-2[69] * | 6 months | 17/42 (40.5) | 2/42 (4.8) | 12/42 (28.6) | ||
| RESOLVE [68] | 12 months | 62/102 (60.8) | 9/49 (18.4) | |||
| RESPOND [73] | 12 months | 37/75 (49.3) | 10/72 (13.9) | 24/73 (32.9) | ||
| RESTORE [48] | 12 months | 43/115 (37.4) | 17/110 (15.5) | 51/118 (43.2) | ||
| Total | 159/334 (47.6) | 179/328 (54.6) | 187/847 (22.1) | 9/49 (18.4) | 182/420 (43.3) | |
Not all treatment groups included in the network meta-analysis are presented. Analysis is based on the intention-to-treat population of each study.
*Data for READ-2 are proportion of patients who gained ≥10 letters (BCVA) from baseline to month 6. After 6 months, patients in the laser treatment arm could receive ranibizumab, preventing meaningful comparisons between treatment arms at 12 months.
BCVA, best-corrected visual acuity; bimonthly, every 2 months; n, number of patients in treatment arm with ≥10 letter increase in BCVA; N, total number of patients in study treatment arm; PRN, pro re nata (as needed).